Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-48433

ABSTRACT: Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI)

OTHER RELATED OMICS DATASETS IN: PRJNA213716PRJNA210119

DISEASE(S): Adenocarcinoma Of Prostate,Pancreatic Adenocarcinoma,Gastric Adenocarcinoma,Acute Lymphoblastic (t-all) Leukemia,Glioblastoma,Anaplastic Astrocytoma,Colon Carcinoma,Renal Carcinoma,Adenocarcinoma, Breast Grown From Mouse Mammary Fat Pad,Lymphoblastic Burkitt's Lymphoma,Large Cell Undifferentiated Lung,Large Cell Lung Carcinoma,Poorly Differentiated Hypernephroma,Ovarian Carcinoma,Acute Lymphoblastic Leukemia,Renal Adenocarcinoma,Carcinoma, Renal Cell,Malignant Amelanocytic Melanoma,Non-small Cell Lung Carcinoma,Aids Related Burkitts Lymphoma,Ovarian Adenocarcinoma,Hepatocellular Carcinoma,Cervical Adenocarcinoma,Squamous Cell Lung Carcinoma,Promyelocytic Leukemia,Melanoma,Malignant Melanoma,Adenocarcinoma Prostate Pc-3 Subline Isolated From Liver Metastasis In Mice,Poorly Differentiated B Cell Origin Leukemia,Adenocarcinoma Her2/erbb2 Transfectant Of Mda-mb-435 Melanoma,Adenocarcinoma Of Colon,Adenocarcinoma Of Lung,Chronic Myelogenous (blast Crisis) Leukemia,Metastatic Malignant Melanoma,Breast Adenocarcinoma

PROVIDER: E-GEOD-48433 | ExpressionAtlas | 2015-09-18

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-48433-analysis-methods.tsv	Tabular
	E-GEOD-48433-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-48433-configuration.xml	Xml
	E-GEOD-48433-percentile-ranks.tsv	Tabular
	E-GEOD-48433.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 1194

Similar Datasets

Homo sapiens

Project description:Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI)

| PRJNA210119 | ENA

NCI60 Expression Profiling using the Agilent Whole Human Genome Oligo Microarray

2010-08-01 | GSE22821 | GEO

NCI60 Expression Profiling using the Agilent Whole Human Genome Oligo Microarray

Project description:We present here a new expression profiling study of the 60 cell lines of the National Cancer Institute (NCI) Developmental Therapeutics program (DTP) drug screen (NCI-60) using the 41,000-probe Agilent Whole Human Genome Oligo Microarray. The expression levels of ∼21,000 genes were measured. The profiling study includes quadruplicate technical replicates for six cell lines and duplicates for the remaining cell lines. The resulting data sets are freely available and searchable online in the CellMiner database (http://discover.nci.nih.gov).

2010-07-31 | E-GEOD-22821 | biostudies-arrayexpress

Role of Anlotinib-induced CCL2 decrease in anti-angiogensis and response prediction for Non-Small Cell Lung Cancer therapy

Project description:Purpose: Our previous clinical trials have been demonstrated that Anlotinib can inhibit tumor growth upon refractory advanced non-small cell lung cancer (NSCLC) patients with the possibility mechanism of anti-angiogenesis. The present study sought to reveal the underlying molecular mechanism of Anlotinib-induced anti-angiogenesis in advanced NSCLC. Experimental Design: Computed tomography (CT) was used to evaluate the treatment effect of Anlotinib upon refractory advanced NSCLC patients. Transcriptome profiling was performed to identify the key gene expression alteration in NCI-H1975 cells before and after Anlotinib treatment. NCI-H1975 derived xenograft model was applied to investigate treatment effect and verify anti-angiogenesis mechanism of Anlotinib. Results: Anlotinib induces tumor cytotoxicity on refractory advanced NSCLC patients, NCI-H1975 derived xenograft models and lung adenocarcinoma cell lines. Transcriptome profiling revealed CCL2 blockade could be responsible for Anlotinib-induced anti-angiogenesis. NCI-H1975 derived xenograft model demonstrated Anlotinib-induced CCL2 blockade play an important role in anti-angiogenesis. Conclusions: This study not only offered the first evidence that Anlotinib inhibits angiogenesis via blocking CCL2 expression, but also provided a novel theoretical basis for the application of Anlotinib in advanced NSCLC patients.

2018-11-30 | E-MTAB-5997 | biostudies-arrayexpress

Expression data for cultured NCI-H1299 parental and spheroid cells as well as their derived xenograft models

Project description:Current approaches to the preclinical investigation for novel cancer therapies rely heavily on the use of traditional cancer cell lines maintained in serum-containing conditions. The discrepancy between promising preclinical efficacy and clinical outcome of most novel anticancer agents emphasizes a need for developing predictive preclinical models that preserve the integrity of original patient tumors, including cancer stem cell (CSC) compartment. In this study, we isolate and characterize CSCs from a non-small cell lung cancer cell line, NCI-H1299, by selectively propagating the cells in a stem-cell culture condition. Isolated CSCs proliferated as nonadherent spheroids, displayed capacity to differentiate and self-renew and exhibited higher tumorigenic potential compared to the parental cells. The gene expression profiles of NCI-H1299 parental cells (serum-containing medium), CSCs (stem-cell medium), and xenograft tumor derived from both cell types were studied by Affymetrix array analysis

2010-07-30 | E-GEOD-21612 | biostudies-arrayexpress

Expression data from uncastrasion and castration tumor from LNCAP Orhotopic xenograft models of prostate cancer

Project description:To identify molecular singnal alterations between androgen dependent prostate cancer and castration resistant prostate cancer, we performed interspecies comparative microarray analyses using RNAs prepared from uncastrasion and castration tumor from LNCAP Orhotopic xenograft models of prostate cancer. microarray data from uncastrasion and castration tumor revealed that the gene expression profile is most significantly altered in between androgen dependent prostate cancer and castration resistant prostate cancer. Comparative analyses of LNCAP Orhotopic xenograft models of prostate cancer showed that genes involved in androgen dependent and androgen independent tumor were significantly altered. We prepared RNA samples from 4 samples uncastrasion and 4 samples castration tumors from LNCAP Orhotopic xenograft models of prostate cancer . High-quality RNA samples were subjected to microarray analysis using the Affymetrix Human Gene 2.0 ST platform, and only those results that passed examinations for quality assurance and quality control of the Human Gene 2.0 ST arrays were retrieved. In total, we obtained gene expression profiles from the following samples: 4 samples uncastrasion and 4 samples castration tumors

2013-04-20 | E-GEOD-46218 | biostudies-arrayexpress

Gene expression data for two xenograft models representing luminal-like and basal-like breast cancer

Project description:Choline (reference 1) and glucose (reference 2) was studied using HR MAS MR spectroscopy data and 105 and 38 gene transcripts were selected respectively from the microarray data to study differences between two xenograft models. Reference 1: Moestue SA et al, Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models, BMC Cancer 2010 Aug 17;10:433 (PMID: 20716336). Reference 2: Grinde et al., submitted The microarray data from the luminal-like and basal-like xenograft models were compared for selected genes, using Limma Bioconducotr package

2010-12-08 | E-GEOD-25915 | biostudies-arrayexpress

Expression data from renal cancer patient-derived xenograft tumor treated with temsirolimus or vehicle

Project description:We kept 2 types of primary xenograft models (KURC;Kyoto University Renal Cancer-1,3) derived from human renal cell carcinoma tissues, and 10 mg/kg of temsirolimus or vehicle was intraperitoneally administered.We performed microarray analysis to compare the gene expression profile of temsirolimus-treated primary xenograft tumors with that of vehicle-treated.

2019-12-31 | GSE133446 | GEO

Regulation of gene expression in ALK inhibitor CH5424802-treated NCI-H2228 xenograft tumors

Project description:To clarify the downstream signal pathway of EML4-ALK in NSCLC, we performed Affymetrix GeneChip analysis using ALK inhibitor CH5424802-treated NCI-H2228 xenograft tumors, and comprehensively characterized the gene expression regulated by inhibition of activated ALK. Mice bearing NCI-H2228 cells were orally administered at dose of 0 (vehicle), 4 or 20 mg/kg of CH5424802, and the tumors were collected and lysed at 6 hours post-dose. Total RNA were extracted from xenograft tumors.

2011-06-03 | E-GEOD-25118 | biostudies-arrayexpress

Expression data from renal cancer xenograft tumor treated with sunitinib or vehicle

Project description:We established 3 types of primary xenograft models (KURC;Kyoto University Renal Cancer-1,2,3) derived from human renal cell carcinoma tissues, and 40 mg/day of sunitinib was orally administered. We performed microarray analysis to compare the gene expression profile of sunitinib-treated primary xenograft tumors (sensitive or resistant status) with that of vehicle-treated.

2015-03-10 | GSE66346 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data